OTCPK:PRLX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Parallax Health Sciences

Executive Summary

Parallax Health Sciences, Inc. builds and expands an integrated digital healthcare network with products and services that provide remote communication, diagnosis, treatment, and monitoring of patients.


Snowflake Analysis

Imperfect balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Parallax Health Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PRLX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.3%

PRLX

0.7%

US Healthcare Services

0.5%

US Market


1 Year Return

-63.1%

PRLX

47.5%

US Healthcare Services

18.7%

US Market

Return vs Industry: PRLX underperformed the US Healthcare Services industry which returned 46.6% over the past year.

Return vs Market: PRLX underperformed the US Market which returned 20.1% over the past year.


Shareholder returns

PRLXIndustryMarket
7 Day5.3%0.7%0.5%
30 Day42.9%3.8%4.9%
90 Day33.3%27.0%19.8%
1 Year-63.1%-63.1%48.0%47.5%21.2%18.7%
3 Year-81.0%-81.0%113.4%112.1%46.2%36.8%
5 Year-42.9%-42.9%150.3%148.0%85.3%65.1%

Price Volatility Vs. Market

How volatile is Parallax Health Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Parallax Health Sciences undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Parallax Health Sciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Parallax Health Sciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of PRLX's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Parallax Health Sciences regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Parallax Health Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

36.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Parallax Health Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of PRLX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Parallax Health Sciences's filings and announcementshere.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Parallax Health Sciences performed over the past 5 years?

15.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PRLX is currently unprofitable.

Growing Profit Margin: PRLX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PRLX is unprofitable, but has reduced losses over the past 5 years at a rate of 15.6% per year.

Accelerating Growth: Unable to compare PRLX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PRLX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-4.8%).


Return on Equity

High ROE: PRLX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Parallax Health Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: PRLX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: PRLX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: PRLX has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: PRLX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PRLX has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: PRLX is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Parallax Health Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PRLX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PRLX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PRLX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PRLX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PRLX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Paul Arena (61 yo)

3.08yrs

Tenure

US$567,815

Compensation

Mr. Paul R. Arena has been the Chairman, Chief Executive Officer and President of AIM Group, Inc. since May 2000. He serves as the Chief Executive Officer and Director of Parallax Health Sciences, Inc. sin ...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD567.82K) is about average for companies of similar size in the US market ($USD582.88K).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Paul Arena
CEO & Chairman of the Board3.08yrsUS$567.82k3.58%
$ 359.0k
Calli Bucci
CFO, Corporate Secretary & Director3.67yrsUS$267.36k3.61%
$ 362.1k
Nathaniel Bradley
CTO & Director2.17yrsUS$227.66kno data
David Stark
President0.42yrno datano data

3.8yrs

Average Tenure

58yo

Average Age

Experienced Management: PRLX's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Paul Arena
CEO & Chairman of the Board3.08yrsUS$567.82k3.58%
$ 359.0k
Calli Bucci
CFO, Corporate Secretary & Director3.67yrsUS$267.36k3.61%
$ 362.1k
Nathaniel Bradley
CTO & Director2.17yrsUS$227.66kno data
John Ogden
Independent Director3.67yrsUS$53.00k1.4%
$ 140.7k
Edward Withrow
Independent Director7.75yrsUS$53.00k0.71%
$ 71.4k

3.7yrs

Average Tenure

61yo

Average Age

Experienced Board: PRLX's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.2%.


Top Shareholders

Company Information

Parallax Health Sciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Parallax Health Sciences, Inc.
  • Ticker: PRLX
  • Exchange: OTCPK
  • Founded: 2005
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$10.041m
  • Shares outstanding: 251.03m
  • Website: https://www.parallaxhealthsciences.com

Number of Employees


Location

  • Parallax Health Sciences, Inc.
  • 1327 Ocean Avenue
  • Suite B
  • Santa Monica
  • California
  • 90401
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PRLXOTCPK (Pink Sheets LLC)YesNew Common StockUSUSDOct 2012

Biography

Parallax Health Sciences, Inc. builds and expands an integrated digital healthcare network with products and services that provide remote communication, diagnosis, treatment, and monitoring of patients. Th ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/14 00:11
End of Day Share Price2020/08/11 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.